CSDD | Jotup

New research highlights a significant and continued gap in achieving diversity in clinical trials of medical therapies

Retrieved on:

Mercredi, juin 21, 2023

Blas, Tufts Center for the Study of Drug Development, Takeda, Clinical trial, MBA, Research, PMP, Associate, Patient, Drug development, CSDD, Shirin David, FDA, DIA, Chief sustainability officer, Pharmaceutical industry, Management, Clario Tech

PHILADELPHIA, June 21, 2023 /PRNewswire/ -- Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, and the Tufts Center for the Study of Drug Development (CSDD) will present the results of new research highlighting critical levels of under-representation by race and ethnicity in pivotal trials supporting drugs and biologics approved between 2007 and 2021.

Key Points:

Preliminary results are to be presented during the Drug Information Association (DIA) 2023 Annual Global Meeting .
Commenting on the research, Otis Johnson, Chief Diversity, Inclusion and Sustainability Officer, Clario, said, "lack of diversity in clinical trials means that the medicines, when approved, may not work for the underrepresented and could harm them.
It enables ease of trial access for a broader pool of participants with the potential to speed up trial enrollment.
It is also good for business, as the approved drugs can be confidently prescribed to a broader, more diverse patient population".

New research highlights a significant and continued gap in achieving diversity in clinical trials of medical therapies

Retrieved on:

Mercredi, juin 21, 2023

PHILADELPHIA, June 21, 2023 /PRNewswire/ -- Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, and the Tufts Center for the Study of Drug Development (CSDD) will present the results of new research highlighting critical levels of under-representation by race and ethnicity in pivotal trials supporting drugs and biologics approved between 2007 and 2021.

Key Points:

Preliminary results are to be presented during the Drug Information Association (DIA) 2023 Annual Global Meeting .
Commenting on the research, Otis Johnson, Chief Diversity, Inclusion and Sustainability Officer, Clario, said, "lack of diversity in clinical trials means that the medicines, when approved, may not work for the underrepresented and could harm them.
It enables ease of trial access for a broader pool of participants with the potential to speed up trial enrollment.
It is also good for business, as the approved drugs can be confidently prescribed to a broader, more diverse patient population".

WCG MAGI Announces: Advance Pricing Ends April 21 for WCG MAGI Clinical Research Conference

Retrieved on:

Lundi, avril 17, 2023

FALLS CHURCH, Va., April 17, 2023 /PRNewswire-PRWeb/ -- Long considered the best value in clinical research, WCG MAGI provides attendees access to more than 45 sessions addressing the biggest challenges in clinical trials and showcasing innovation that is igniting change throughout the industry. The best value in clinical research is at its best value now, with Advance pricing savings of $200 off registration.

Key Points:

Advance pricing ends April 21 for WCG MAGI Clinical Research Conference — 2023 East.
This unique 3.5-day event connects more than 600 clinical research professionals who share a deep commitment to ensuring the quality, compliance, and efficiency of clinical research that is needed to advance the delivery of therapies and devices that impact patients' lives.
FALLS CHURCH, Va., April 17, 2023 /PRNewswire-PRWeb/ -- Long considered the best value in clinical research, WCG MAGI provides attendees access to more than 45 sessions addressing the biggest challenges in clinical trials and showcasing innovation that is igniting change throughout the industry.
The best value in clinical research is at its best value now, with Advance pricing savings of $200 off registration.

BLOCKCHAIN BRINGS THE FIGHT TO $40B FOOD FRAUD ECONOMY

Retrieved on:

Jeudi, avril 6, 2023

Accreditation, Consumer Brands Association, Prevalence, Civil service commission, Produce traceability, Food industry, Carbon footprint, DPP, Sale, NFU Mutual, ESPR, Traceability, CSDD, Randy Wright, EC, European Commission, Pharmaceutical industry, Cryptocurrency

OSLO, Norway, April 6, 2023 /PRNewswire/ -- In the aftermath of the recent false labeling controversy of foreign pork as British, the UK honey debacle, and a plethora of other cases, the prevalence of food fraud is at an all-time high. Renowned organisations have been impacted by serious food fraud incidents over the last decade. This 'shadow economy' currently impacts over 10% of the global supply chain and costs the industry $40billion annually, according to The Consumer Brands Association.

Key Points:

Renowned organisations have been impacted by serious food fraud incidents over the last decade.
It is not only the economic impact of food fraud, but also potential health consequences and knock-on, reputational damage for brands across the sector.
According to NFU Mutual , 72% of consumers believe there to be an issue with food fraud in the UK, and only 12% have confidence in the European food chain.
Food integrity has been a growing issue for policymakers, food systems, and consumers for many years.

BLOCKCHAIN BRINGS THE FIGHT TO $40B FOOD FRAUD ECONOMY

Retrieved on:

Jeudi, avril 6, 2023

OSLO, Norway, April 6, 2023 /PRNewswire/ -- In the aftermath of the recent false labeling controversy of foreign pork as British, the UK honey debacle, and a plethora of other cases, the prevalence of food fraud is at an all-time high. Renowned organisations have been impacted by serious food fraud incidents over the last decade. This 'shadow economy' currently impacts over 10% of the global supply chain and costs the industry $40billion annually, according to The Consumer Brands Association.

Key Points:

Renowned organisations have been impacted by serious food fraud incidents over the last decade.
It is not only the economic impact of food fraud, but also potential health consequences and knock-on, reputational damage for brands across the sector.
According to NFU Mutual , 72% of consumers believe there to be an issue with food fraud in the UK, and only 12% have confidence in the European food chain.
Food integrity has been a growing issue for policymakers, food systems, and consumers for many years.

nChain and Unisot in Strategic Partnership to boost Supply Chain Traceability

Retrieved on:

Jeudi, février 16, 2023

LONDON, Feb. 16, 2023 /PRNewswire/ -- nChain, a global leader in the creation and delivery of Web3 solutions through Research and Development and the implementation of blockchain technology, today announces the signing of a strategic partnership agreement with UNISOT, a leading Platform as a Service enabling supply chain traceability.

Key Points:

LONDON, Feb. 16, 2023 /PRNewswire/ -- nChain, a global leader in the creation and delivery of Web3 solutions through Research and Development and the implementation of blockchain technology, today announces the signing of a strategic partnership agreement with UNISOT, a leading Platform as a Service enabling supply chain traceability.
With UNISOT, we are particularly proud of being able to provide the technology for a solution that allows full transparency of the supply chain as well as 360 global interoperability from the source to the recycling point.
Stephan Nilsson, CEO and Co-founder, UNISOT, said: "nChain is the partner of choice for us for several reasons.
UNISOT's Web3 platform enables supply chain players of all sizes to participate in the global information flow, from small farmers to multinational giants to consumers.

nChain and Unisot in Strategic Partnership to boost Supply Chain Traceability

Retrieved on:

Jeudi, février 16, 2023

LONDON, Feb. 16, 2023 /PRNewswire/ -- nChain, a global leader in the creation and delivery of Web3 solutions through Research and Development and the implementation of blockchain technology, today announces the signing of a strategic partnership agreement with UNISOT, a leading Platform as a Service enabling supply chain traceability.

Key Points:

LONDON, Feb. 16, 2023 /PRNewswire/ -- nChain, a global leader in the creation and delivery of Web3 solutions through Research and Development and the implementation of blockchain technology, today announces the signing of a strategic partnership agreement with UNISOT, a leading Platform as a Service enabling supply chain traceability.
With UNISOT, we are particularly proud of being able to provide the technology for a solution that allows full transparency of the supply chain as well as 360 global interoperability from the source to the recycling point.
Stephan Nilsson, CEO and Co-founder, UNISOT, said: "nChain is the partner of choice for us for several reasons.
UNISOT's Web3 platform enables supply chain players of all sizes to participate in the global information flow, from small farmers to multinational giants to consumers.

AI in Bio Pharmaceuticals Research Report 2022 - ResearchAndMarkets.com

Retrieved on:

Mercredi, mai 11, 2022

The "AI in Bio Pharmaceuticals" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "AI in Bio Pharmaceuticals" report has been added to ResearchAndMarkets.com's offering.
AI is regarded by some top executives at big pharma (Novartis, Pfizer, GSK and others) as a tool to uncover not only new molecules but also new targets.
The technology providers in Pharmaceutical Industry are profiled in the report into 6 categories: Artificial Intelligence (R&D Platforms), Quantum Computing, Supporting Services, "Big Tech" Corporations, Autonomous Labs, and Big Data Providers.
What are the recent investments, deals, and collaboration for AI in pharma?

QUOTIENT SCIENCES COMPLETES INTEGRATION OF DRUG SUBSTANCE INTO TRANSLATIONAL PHARMACEUTICS® PLATFORM

Retrieved on:

Jeudi, février 17, 2022

Quotient, Patient, Drug development, CEO, Tufts Center for the Study of Drug Development, CSO, Solution, FIH, CSDD, FDA, Acquisition, POC, Trial of the century, Industry, MHRA, Pharmaceutical industry

The newly integrated service unites drug substance, drug product and clinical testing activities all within a unifiedorganization and under a single project manager.

Key Points:

The newly integrated service unites drug substance, drug product and clinical testing activities all within a unifiedorganization and under a single project manager.
Quotient Sciences Translational Pharmaceuticsapproach combining manufacturing and clinical dosing at a single organization enables innovators to adjust formulations and dosing in real time.
"In fact, an independent study by the Tufts Center of the Study of Drug Development (CSDD) showed Translational Pharmaceutics delivered $200milllion in drug development cost saving per approved drug."
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway.

QUOTIENT SCIENCES COMPLETES INTEGRATION OF DRUG SUBSTANCE INTO TRANSLATIONAL PHARMACEUTICS(R) PLATFORM

Retrieved on:

Jeudi, février 17, 2022

NOTTINGHAM (UK), February 17, 2022: Quotient Sciences - a global drug development and manufacturing accelerator offering a suite of services to clients in the pharmaceutical and biotech industry - announces that it has integrated drug substance into its flagship Translational Pharmaceutics(R) platform .

Key Points:

NOTTINGHAM (UK), February 17, 2022: Quotient Sciences - a global drug development and manufacturing accelerator offering a suite of services to clients in the pharmaceutical and biotech industry - announces that it has integrated drug substance into its flagship Translational Pharmaceutics(R) platform .
The newly integrated service unites drug substance, drug product and clinical testing activities all within a unified organization and under a single project manager.
Quotient Sciences Translational Pharmaceutics(R) approach - combining manufacturing and clinical dosing at a single organization - enables innovators to adjust formulations and dosing in real time.
"By fully integrating drug substance with drug product and clinical testing activities, Quotient Sciences can closely align manufacturing and dosing workflows, greatly improving R&D efficiencies, and increasing the potential for clinical and commercial success," stated Peter Scholes, CSO of Quotient Sciences.